Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avanti Acquisition Corp.AVAN · Entity 146146 | Director | October 01, 2020 | October 05, 2020 |
| Guardant Health, Inc.GH · Entity 3238 | Director | September 21, 2026 | September 22, 2026 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director | September 19, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avanti Acquisition Corp.
Report date October 01, 2020 · Filed October 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Units, consisting of Class A ordinary share and one-half ofSEC Table I · non-derivative | IndirectSee Footnote | 1,000,000 |
Reported balance
After 2020-10-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-10-01 · Purchase · Acquired 1,000,000 · Balance 1,000,000 F1: The units disclosed in Table I were purchased in the Issuer's initial public offering. Such units of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the units held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the units held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the units held of record by the Funds for purposes of Section 16, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The units disclosed in Table I were purchased in the Issuer's initial public offering. Such units of this Form 4 are held of record by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd. (the "Funds"). Bridger Management, LLC is the investment adviser to the Funds and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the units held of record by the Funds. Mr. Mignone disclaims beneficial ownership of the units held of record by the Funds except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the units held of record by the Funds for purposes of Section 16, or for any other purpose.
Guardant Health, Inc.
Report date September 21, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,274 |
Reported balance
After 2026-09-21 transaction · row 1
1 source rowRow 1 · 2026-09-21 · Exercise / conversion · Acquired 264 · Balance 10,274 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 6,600 |
Reported balance
After 2026-09-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-21 · Exercise / conversion · Disposed 264 · Balance 6,600 F1: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter.
F2: Not applicable for Restricted Stock Units.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date September 19, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Indirect[see footnote] | 0 |
Reported balance
After 2026-09-18 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-18 · Sale · Disposed 367,600 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.68 to $39.38, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2: The 367,600 Ordinary Shares disclosed in Table I of this Form 4 were held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone was deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaimed beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone was the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 119,807 |
Reported balance
Holding disclosure · report date 2026-09-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 119,807 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.68 to $39.38, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2: The 367,600 Ordinary Shares disclosed in Table I of this Form 4 were held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone was deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaimed beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone was the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cardiff Oncology, Inc.
Report date November 11, 2016 · Filed November 15, 2016
Jointly reported with BRIDGER MANAGEMENT, LLC
Section 16 reporting ended · disclosed 2016-11-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par value per shareSEC Table I · non-derivative | IndirectSee footnotes | 2,968,115 |
Reported balance
After 2016-11-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2016-11-11 · Purchase · Disposed 322,472 · Balance 2,968,115 F1: The price reported in Column 4 is a weighted average price, rounded to the nearest whole cent. These Shares (as defined below) were sold in multiple transactions at prices ranging from $3.00 to $3.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2: The shares of Common Stock, $.0001 par value per share (the "Shares"), reported herein as indirectly beneficially owned by the Reporting Persons are held of record by Swiftcurrent Partners, L.P., Swiftcurrent Offshore Master Ltd. and Bridger Healthcare Ltd. Bridger Management LLC is the investment adviser to Swiftcurrent Partners L.P., Swiftcurrent Offshore Master Ltd., and Bridger Healthcare Ltd., and as such, may be deemed to share beneficial ownership of the Shares. Roberto Mignone is the manager of Bridger Management, LLC. F3: Each reporting person and entity named herein disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein and this report shall not be deemed an admission that the reporting person or any entity named herein is the beneficial owner of the securities for purposes of Section 16, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price, rounded to the nearest whole cent. These Shares (as defined below) were sold in multiple transactions at prices ranging from $3.00 to $3.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, full information regarding the number of Shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: The shares of Common Stock, $.0001 par value per share (the "Shares"), reported herein as indirectly beneficially owned by the Reporting Persons are held of record by Swiftcurrent Partners, L.P., Swiftcurrent Offshore Master Ltd. and Bridger Healthcare Ltd. Bridger Management LLC is the investment adviser to Swiftcurrent Partners L.P., Swiftcurrent Offshore Master Ltd., and Bridger Healthcare Ltd., and as such, may be deemed to share beneficial ownership of the Shares. Roberto Mignone is the manager of Bridger Management, LLC.
F3: Each reporting person and entity named herein disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein and this report shall not be deemed an admission that the reporting person or any entity named herein is the beneficial owner of the securities for purposes of Section 16, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2026 Filed Sep 22, 2026 20:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000018 · wk-form4_1790109186.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,600 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 21, 2026 Filed Sep 22, 2026 20:33 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000018 · wk-form4_1790109186.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 20:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 367,600 | $39.06 | $14,356,801.80 |
DisclosureSEC source: 0001193125-26-397959 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · [see footnote] Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.68 to $39.38, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The 367,600 Ordinary Shares disclosed in Table I of this Form 4 were held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone was deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaimed beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone was the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000016 · wk-form4_1787606446.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,864 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000016 · wk-form4_1787606446.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 21:15 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000014 · wk-form4_1784754937.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,128 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 21, 2026 Filed Jul 22, 2026 21:15 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000014 · wk-form4_1784754937.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2026 Filed Jun 23, 2026 21:28 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000012 · wk-form4_1782250080.xml · derivative · entry 4 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,392 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 21, 2026 Filed Jun 23, 2026 21:28 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000012 · wk-form4_1782250080.xml · nonDerivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:54 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 2,711 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000010 · wk-form4_1782165246.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,711 Underlying: Common Stock · 2,711 shares Expires not disclosed F3 · derivative.exercise_date: The restricted stock unit award vests in full on the one-year anniversary of the grant date, June 17, 2026, or the date of the Company's next annual meeting of stockholders, whichever is earlier. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 4,203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000010 · wk-form4_1782165246.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award vested in full on the date of the 2026 Annual Meeting of Stockholders which was held on June 17, 2026. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 21:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 4,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000010 · wk-form4_1782165246.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,954 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-261672 · ownership.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F4 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vested on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 14,492 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-261672 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 7,242 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-251372 · ownership.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,242 Underlying: Ordinary Shares · 7,242 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F2 · derivative.expiration_date: Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| May 21, 2026 Filed Jun 23, 2026 21:28 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000012 · wk-form4_1782250080.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,656 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| May 21, 2026 Filed Jun 23, 2026 21:28 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000012 · wk-form4_1782250080.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000008 · wk-form4_1776896254.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,920 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on October 21, 2025 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 21, 2026 Filed Apr 22, 2026 22:17 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000008 · wk-form4_1776896254.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,751 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2026 Filed Mar 23, 2026 20:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000006 · wk-form4_1774297172.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,184 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 21, 2026 Filed Mar 23, 2026 20:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000006 · wk-form4_1774297172.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2026 Filed Feb 23, 2026 22:47 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000004 · wk-form4_1771886819.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,448 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| February 21, 2026 Filed Feb 23, 2026 22:47 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000004 · wk-form4_1771886819.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:44 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000002 · wk-form4_1769121885.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,712 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 22:44 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-26-000002 · wk-form4_1769121885.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2025 Filed Dec 24, 2025 00:25 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-25-000010 · wk-form4_1766535945.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,976 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| December 21, 2025 Filed Dec 24, 2025 00:25 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-25-000010 · wk-form4_1766535945.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 77,400 | $30.24 | $2,340,645.66 |
DisclosureSEC source: 0001193125-25-324780 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · [see footnote] Disclosed balance after: 367,600 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.225 to $30.25, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The 367,600 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. Read SEC document |
| November 26, 2025 Filed Dec 1, 2025 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 50,000 | $26.03 | $1,301,505.00 |
DisclosureSEC source: 0001193125-25-303849 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · [see footnote] Disclosed balance after: 445,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 to $26.035, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The 445,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 264 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-25-000008 · wk-form4_1764026509.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,240 Underlying: Common Stock · 264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| November 21, 2025 Filed Nov 24, 2025 23:21 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-25-000008 · wk-form4_1764026509.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2025 Filed Nov 10, 2025 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 200,000 | $24.11 | $4,821,880.00 |
DisclosureSEC source: 0001193125-25-274286 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · [see footnote] Disclosed balance after: 495,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.0050 to $24.2450, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The 495,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 23:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 3,167 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001258394-25-000006 · wk-form4_1761174473.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,504 Underlying: Common Stock · 3,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock unit granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024, and the remaining 75% vests monthly over the three-year period thereafter. F2 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 23:07 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 3,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001258394-25-000006 · wk-form4_1761174473.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:39 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 4,203 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000203 · wk-form4_1750455549.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,203 Underlying: Common Stock · 4,203 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:39 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantStock Option (Right to Buy) · Derivative | 6,833 | $0.00 Strike: $50.57 | $0.00 |
DisclosureSEC source: 0001576280-25-000203 · wk-form4_1750455549.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,833 Underlying: Common Stock · 6,833 shares Expires 2035-06-18 F1 · derivative.exercise_date: The stock option vests in full on the one-year anniversary of the grant date, June 18, 2025 or the date of the next year annual stockholders meeting, whichever is earlier. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083687 · ownership.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F4 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vested on June 6, 2025. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 20:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 9,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-083687 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:03 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 14,492 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083687 · ownership.xml · derivative · entry 4 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,492 Underlying: Ordinary Shares · 14,492 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F5 · derivative.exercise_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F5 · derivative.expiration_date: Restricted share units were granted on June 5, 2025 and vest on June 5, 2026. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| December 20, 2024 Filed Dec 26, 2024 21:02 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 286,000 | $22.01 | $6,294,030.60 |
DisclosureSEC source: 0000950170-24-140391 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · [see footnote] Disclosed balance after: 695,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.82 to $22.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The 695,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund, Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 23:06 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantRestricted Stock Units · Derivative | 12,671 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-24-000263 · wk-form4_1731452768.xml · derivative · entry 2 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,671 Underlying: Common Stock · 12,671 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock unit granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of October 21, 2024, and the remaining 75% vests monthly for the three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| November 08, 2024 Filed Nov 12, 2024 23:06 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantStock Option (Right to Buy) · Derivative | 19,535 | $0.00 Strike: $28.61 | $0.00 |
DisclosureSEC source: 0001576280-24-000263 · wk-form4_1731452768.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,535 Underlying: Common Stock · 19,535 shares Expires 2034-11-08 F1 · derivative.exercise_date: The stock option granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award will vest on the one-year anniversary of October 21, 2024, and the remaining 75% vests monthly for the three-year period thereafter. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 20:05 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 519,000 | $17.03 | $8,838,570.00 |
DisclosureSEC source: 0000950170-24-076225 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · [see footnote] Disclosed balance after: 981,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.96 to $17.16, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The 981,000 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund, Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 12:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074025 · ownership.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F4 · derivative.expiration_date: Restricted Share Units were granted on June 15, 2023 and vested on June 15, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| June 15, 2024 Filed Jun 17, 2024 12:00 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 21,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-074025 · ownership.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,595,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 11:45 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 9,632 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071072 · ownership.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,632 Underlying: Ordinary Shares · 9,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F2 · derivative.expiration_date: Restricted share units were granted on June 6, 2024 and vest on June 6, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-044784 · doc4.xml · derivative · entry 3 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F4 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2023 Filed Aug 7, 2023 20:06 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 15,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-044784 · doc4.xml · nonDerivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,574,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 11:35 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 21,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038221 · doc4.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,108 Underlying: Ordinary Shares · 21,108 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F2 · derivative.expiration_date: Restricted share units were granted on June 15, 2023 and vest on June 15, 2024. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 11:21 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 15,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044694 · doc4.xml · derivative · entry 1 MIGNONE ROBERTO · CIK 0001258394 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,810 Underlying: Ordinary Shares · 15,810 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on August 4, 2022 and vest on August 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.